Target intelligence / Profile preview

26S proteasome non-ATPase regulatory subunit 4 (PSMD4)

Target
PSMD4
Molecular classification
Proteasome subunit, Ubiquitin receptor, Other
01

Overview

Proteasome 26S subunit non-ATPase 4 (PSMD4), also known as Rpn10 or S5a, is an essential non-ATPase subunit of the 19S regulatory particle of the 26S proteasome. It functions primarily as a ubiquitin receptor, utilizing its ubiquitin-interacting motifs (UIMs) to recognize and bind polyubiquitinated proteins, thereby facilitating their delivery to the 20S core particle for degradation. PSMD4 plays a critical role in maintaining cellular protein homeostasis, regulating the cell cycle, apoptosis, and antigen presentation. In disease states, PSMD4 is frequently overexpressed in various malignancies, such as multiple myeloma, hepatocellular carcinoma, and colorectal cancer, where it promotes tumor cell survival and contributes to chemoresistance. Conversely, its dysregulation is also implicated in neurodegenerative disorders due to the accumulation of toxic protein aggregates. Therapeutic targeting of PSMD4, such as with the small-molecule inhibitor SB699551, represents a promising strategy to selectively induce apoptosis in cancer cells and overcome resistance to traditional proteasome inhibitors without directly blocking the catalytic activity of the 20S core.

Other names
Proteasome 26S subunit non-ATPase 426S proteasome regulatory subunit Rpn1026S proteasome regulatory subunit S5AS5aRpn10Multiubiquitin chain-binding proteinAntisecretory factor 1ASFAFAngiocidinpUB-R5MCB1
02

Mechanism of action

Inhibition of ubiquitin receptor function by blocking the binding of polyubiquitinated proteins to the 19S regulatory particle, thereby preventing substrate delivery to the 20S catalytic core.

03

Biological functions

Protein degradationUbiquitin-dependent protein catabolic processCell cycle regulationApoptosisAntigen presentationAutophagySignal transduction
04

Disease associations

CancerMultiple myelomaHepatocellular carcinomaColorectal cancerNeurodegenerative diseaseAlzheimer's diseaseParkinson's diseaseInflammation
05

Safety considerations

Off-target toxicityBroad biological effects due to proteasome inhibitionAccumulation of misfolded proteins in normal cellsPotential for systemic toxicityImpaired protein quality control
06

Interacting drugs

07

Biomarkers

PSMD4 expression level1q21 copy numberNrf2 expression levelCytoplasmic Nrf2 localization

Beyond the preview

Go deeper on 26S proteasome non-ATPase regulatory subunit 4 (PSMD4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 26S proteasome non-ATPase regulatory subunit 4 (PSMD4).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call